Clinical Trial Update: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy [Phase 1]

View source ↗

Summary

A National Cancer Institute-sponsored Phase 1 trial evaluating sunitinib malate in HIV-positive cancer patients on antiretroviral therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• HIV Infection
• Hodgkin Lymphoma
• Langerhans Cell Histiocytosis
• Non-hodgkin Lymphoma

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED